Marshall Wace’s Gain Therapeutics GANX Stock Holding History

Marshall Wace’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.43M	Buy	1,769,788 +107,495	+6%	+$234K	﹤0.01%	1500
2025 Q4	$5.35M	Buy	1,662,293 +1,487,186	+849%	+$3.97M	﹤0.01%	1121
2025 Q3	$310K	Sell	175,107 -101,326	-37%	-$171K	﹤0.01%	2414
2025 Q2	$498K	Buy	276,433 +80,407	+41%	+$149K	﹤0.01%	2144
2025 Q1	$374K	Buy	196,026 +104,288	+114%	+$231K	﹤0.01%	2188
2024 Q4	$198K	Buy	+91,738	New	+$184K	﹤0.01%	2355

Other funds holding GANX

PCM

Potomac Capital Management New York $115M AUM

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace's GANX Position: Q1 2026 in Review

Marshall Wace increased its Gain Therapeutics (GANX) stake by 6.5% in Q1 2026, buying an estimated $234K and bringing the position to 1,769,788 shares worth $3.43M. The position accounts for ﹤0.01% of the portfolio, ranked #1500.

Marshall Wace first reported a position in GANX in Q4 2024 and has held it in 6 quarters since. The position peaked at $5.35M in Q4 2025. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

Marshall Wace held 1,769,788 shares of Gain Therapeutics worth $3.43M as of Q1 2026.
Marshall Wace bought 107,495 Gain Therapeutics shares in Q1 2026, an estimated $234K.
Gain Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1500 holding.
Marshall Wace first reported a position in Gain Therapeutics in Q4 2024 and has held it in 6 quarters since.
Marshall Wace's Gain Therapeutics position peaked at $5.35M in Q4 2025.
42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.